Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Wedbush PacGrow Healthcare Virtual Conference Transcript

Aug 12, 2020 / 05:45PM GMT
Release Date Price: €44.44 (-2.07%)
Laura Kathryn Chico
Wedbush Securities Inc., Research Division - SVP of Equity Research

Thanks, everybody, for joining us today. My name is Laura Chico. I am one of the senior biotech analysts at Wedbush. It is my great pleasure to introduce our next presenting company, Sage therapeutics. And joining us today, we have CEO, Jeff Jonas. Jeff, I am thrilled to have you here today. Thank you so much for participating.

Before I pass it over to Jeff, let me just set the agenda real brief. First, we'll get started with Jeff delivering some introductory remarks, a brief overview to Sage and giving us a quick update on recent developments. And then we will transition to Q&A with the remaining time. (Operator Instructions)

So Jeff, with that, I will turn the floor over to you.

Jeffrey M. Jonas
Sage Therapeutics, Inc. - CEO, President & Director

Thanks. Firstly, thank you, everybody, for joining us today. Hope everyone is healthy and your family and friends are all healthy. I'm going to be really brief because I know people don't need to hear

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot